Mechanism of Acid Hypersecretion Post Curative Gastrinoma Resection
Overview
Affiliations
Background: Some patients with Zollinger-Ellison syndrome post curative gastrinoma resection continue to show gastric acid hypersecretion; however, the mechanism is unknown.
Aim: The aim of this study was to prospectively study acid secretion following curative gastrinoma resection and analyze factors contributing in patients with Zollinger-Ellison syndrome.
Methods: Fifty patients cured post gastrinoma resection were studied with serial assessments of acid secretory status, cure status and ECL-cell status/activity (with serial biopsies, CgA, urinary N-MIAA). Correlative analysis was performed to determine predictive factors.
Results: Hypersecretion occurred in 31 patients (62%) and 14 had extreme-hypersecretion. There was an initial decline (3-6 months) in BAO/MAO, which then remained stable for eight years. Preoperative BAO correlated with the postoperative secretion, but not other clinical, tumoral, laboratory variables, the degree of postoperative acid suppression or type of antisecretory drug needed. Hypersecretors had greater postoperative ECL changes (P=0.005), serum CGA (P=0.009) and 24-h urinary N-MIAA (P=0.0038).
Conclusions: Post curative resection, gastric hypersecretion persists long term (mean 8 years) in 62% of patients and in 28% it is extreme, despite normogastrinemia. No preoperative variable except BAO correlates with postresection hypersecretion. The persistent increased ECL-cell extent post curative resection suggests prolonged hypergastrinemia can lead to changes in ECL-cells that are either irreversible in humans or sustained by unknown mechanisms not involving fasting hypergastrinemia and which can result in hypersecretion, in a proportion of which it can be extreme. Whether similar findings may occur in patients with idiopathic GERD treated for prolonged periods (>10 years) with PPIs, at present, is unknown.
Wydra A, Cylke-Falkowska K, Czajka-Oraniec I, Kolasinska-Cwikla A, Cwikla J, Zgliczynski W Front Endocrinol (Lausanne). 2023; 14:1135016.
PMID: 37008936 PMC: 10061007. DOI: 10.3389/fendo.2023.1135016.
Frey S, Mirallie E, Le Bras M, Regenet N Cancers (Basel). 2021; 13(23).
PMID: 34885063 PMC: 8656750. DOI: 10.3390/cancers13235954.
Gastrinoma in multiple endocrine neoplasia type 1 after total pancreatectomy: A case report.
Gong S, Li Z, Liu X, Wang X, Shen W Medicine (Baltimore). 2019; 98(50):e18275.
PMID: 31852099 PMC: 6922403. DOI: 10.1097/MD.0000000000018275.
Lee L, Ramos-Alvarez I, Ito T, Jensen R Int J Mol Sci. 2019; 20(20).
PMID: 31623145 PMC: 6829234. DOI: 10.3390/ijms20205128.
Gastrinomas: Medical or Surgical Treatment.
Norton J, Foster D, Ito T, Jensen R Endocrinol Metab Clin North Am. 2018; 47(3):577-601.
PMID: 30098717 PMC: 6092039. DOI: 10.1016/j.ecl.2018.04.009.